Upfront Briefing
Deal desks earned their keep again: Chiesi paid $1.9B for KalVista's launched oral HAE pill (KALV +39%), Teva put $700M upfront on Emalex's NDA-ready Tourette's asset, and AstraZeneca exercised its option on Pinetree's antibody-based EGFR degrader (small $25M check, big modality signal).
Outside dealflow: AbbVie's Q1 print was a beat-and-raise but came with a BTK degrader shutdown and a CRL on its BoNT/E candidate; Biogen leaned harder into early-stage assets to rebuild the equity story.
Macro tape was Fed-and-oil, not risk-on — small caps and biotech absorbed the dual hit (Russell -0.6%, XBI -1.7%) while Mag 7 earnings after the bell set a softer Thursday open.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,136.0 |
0.0% |
+4.6% |
| Nasdaq 100 |
27,187.0 |
+0.6% |
+7.8% |
| Russell 2000 |
2,739.5 |
(0.6%) |
+10.5% |
| Healthcare (XLV) |
142.8 |
(0.7%) |
(7.1%) |
| Biotech (XBI) |
128.9 |
(1.7%) |
+7.6% |
| Nasdaq Biotech (NBI) |
5,753.9 |
(1.3%) |
+0.4% |
| Clinical Trials (BBC) |
42.8 |
(2.9%) |
+14.4% |
|
- Wednesday was a Fed-and-oil tape, not a clean risk-on session: the FOMC held rates at 3.5–3.75% in an unusually divided 8–4 vote, Treasury yields moved higher, and Brent kept rallying on Iran-blockade fears — leaving small caps and healthcare on the wrong side of both moves (Russell 2000 −0.6%, XLV −0.7%).
- Biotech beta took the cleaner hit: XBI −1.7%, NBI −1.3%, BBC −2.9%, with the cohort still digesting Monday's Compass/CMPX OS miss and Tuesday's Erasca pneumonitis death even as KalVista (+39%) supplied a single-name M&A offset. Mega-cap earnings also leaned less supportive after the bell, with Meta down more than 6% on AI capex concerns.
- Market data: U.S. close Wed 29-Apr-2026.
The Big 3
|
1
|
Chiesi to acquire KalVista in $1.9B HAE deal
|
- Chiesi agreed to acquire KalVista for ~$1.9B at $27/share cash — a 40% premium to Tuesday's close — picking up Ekterly (sebetralstat), the only oral on-demand HAE therapy, FDA-approved July 2025. KALV +39% on the day, on volume 33x its 3-month average. Closing expected Q3 2026; this is Chiesi's largest deal to date.
- Why it matters: Three reads. (1) Asset: Ekterly is the first oral on-demand HAE pill — a structural disruption to an injectable-anchored category dominated by Takeda's Firazyr/Takhzyro and CSL's Haegarda; commercial uptake will set the ceiling for Chiesi's milestone-implied returns. (2) Comp: $27/share gives the HAE group a fresh scarcity-value marker and creates a direct read-through to Pharvaris, whose oral bradykinin B2 antagonist sits in the same on-demand HAE conversation. (3) Sector: Strategic buyers will still pay a premium for de-risked, recently-launched orphan franchises with first-/best-in-class profiles, even with a CRL in the recent regulatory backdrop — a constructive marker for any commercial-stage rare-disease names trading below recent highs.
- Source: BioCentury; STAT
|
|
2
|
Teva to acquire Emalex with $700M upfront for Tourette’s
|
- Teva agreed to acquire VC-backed Emalex Biosciences for $700M cash upfront plus up to $200M in commercial milestones and royalties on global net sales — total potential value ~$900M+. The deal hands Teva ecopipam, a first-in-class selective D1 receptor antagonist that hit primary and secondary endpoints in the Phase 3 D1AMOND study (NCT05615220) in Feb 2025; NDA submission anticipated 2H 2026. Emalex was founded by Paragon Biosciences in 2018; backers included Bain Capital Life Sciences (lead Series D), Paragon, Valor Equity Partners and Fidelity.
- Why it matters: (1) Asset: Ecopipam would be the first non-antipsychotic, non-VMAT2 mechanism approved in Tourette's — a category where Teva already commercializes Austedo and where the unmet need sits on tolerability rather than efficacy; D1-selective antagonism gives Teva line-extension optionality across pediatric neuropsych. (2) Pricing: $700M upfront + up to $200M milestones for a single Phase 3-positive CNS asset 12 months post-readout sets a useful comp for late-stage neuro M&A — implies buyers will pay full-freight for prospectively-controlled, pivotal-positive packages even in a specialist neuro indication. The 78%/22% upfront/contingent split also reads as buyer conviction rather than a milestone-heavy "biobucks" structure. (3) Read-through: A reminder that single-asset, single-indication CNS biotechs with NDA-ready packages can still clear $500M+ upfronts — relevant for VCs sitting on Phase 3 neuro names (e.g., MapLight, Atai).
-
Source:
BioCentury
|
| 3 | AstraZeneca exercises option on Pinetree EGFR degrader |
-
AstraZeneca exercised its option on Pinetree's PTX-299, a preclinical first-in-class bispecific antibody degrader targeting EGFR built on Pinetree's AbReptor platform. The exercise triggered a $25M closing payment; AZ now takes global development and commercialization, with total deal value above $500M including milestones and tiered royalties. Original option signed July 2024.
-
Why it matters:
(1) Asset: PTX-299 isn't a small-molecule degrader — it's an antibody-based degrader designed to remove membrane-bound and extracellular EGFR rather than inhibit kinase activity, which is mechanistically positioned against TKI resistance modes (C797S, MET amplification) where kinase inhibition can struggle. (2) Strategic: $25M is small for AZ but the option exercise is a pre-clinical conviction signal — AZ now has Tagrisso as the EGFR backbone and PTX-299 as a preclinical degrader option on the same biology, extending the franchise beyond kinase inhibition before Tagrisso LOE pressure intensifies later in the decade. (3) Modality: Validates antibody-based degradation as a distinct sub-modality from chimeric/molecular-glue approaches — read-through for Genentech/Nurix, Arvinas/Pfizer, Foghorn, and other TPD plays. The same week, AbbVie discontinued its BTK degrader ABBV-101 (see Everything Else) — degrader space is bifurcating fast between winners and shutdowns.
-
Source:
PR
|
Everything Else that broke
- AbbVie (ABBV) topped Q1 2026 estimates and raised full-year guidance, but disclosed two pipeline negatives: (i) discontinued BTK degrader ABBV-101 (M23-647 Phase 1 in r/r NHL) — company said decision was independent of trial results; and (ii) received an FDA Complete Response Letter for trenibotulinumtoxinE (trenibotE) — first-in-class fast-onset/short-duration BoNT/E — over manufacturing process information. Stock bounced from 8-month lows post-print. — PR; BioSpace
- Biogen (BIIB) Q1 2026 print showed growth curve trending up across Leqembi, Skyclarys and Zurzuvae, with management refocusing the next-leg narrative on early-stage assets — including felzartamab (kidney) and the lupus pair litifilimab/dapirolizumab pegol — to address what one sell-side note called "lackluster investor appeal." Useful read for the broader large-cap-biotech rotation thesis. — BioSpace
- Phase 3 data for denecimig (Mim8) were published in NEJM, with a claim of reduced annualized bleeding rate regardless of inhibitor status. Peer-reviewed results can sharpen the regulatory and commercial case in prophylaxis. — PR
- Orchard Therapeutics received a UK Innovation Passport designation for OTL-201 in MPS-IIIA. The designation can support acceleration pathways and access planning for an ultra-rare gene therapy. — PR
- A PR statement said China’s NMPA granted marketing authorization for recombinant botulinum toxin type A Retoxin from Claruvis. The authorization could open a commercial footprint in China for aesthetics and therapeutics. — PR
- BioSpace reported the FDA’s end to a 9-month advisory committee drought as a “narrow restart.” Advisory committee cadence can affect timing and perceived certainty of late-stage FDA decisions. — BioSpace
- BioCentury reported that a tiny biotech’s experience raised questions about FDA rare-disease policies. The report pointed to uncertainty around flexibility on rare-disease frameworks and CMC expectations. — BioCentury
- OSE Immunotherapeutics reported full-year 2025 unaudited consolidated financial results and its Q1 2026 cash position. Cash updates inform runway and dilution risk for clinical programs. — PR
- Nicox provided full-year 2025 financial results and a corporate update. The disclosures can change expectations for funding needs and upcoming milestones. — PR
- Addex reported full-year 2025 financial results and provided a corporate update. The update can shift expectations for cash needs and program prioritization. — PR
- Vaccinex reported 2025 annual financial results. Annual financials help investors assess burn rate and the likelihood of additional capital raising. — PR
- Roche said it will present extensive data on its ophthalmology portfolio at ARVO 2026. Conference disclosures can shape expectations for commercial assets and pipeline programs in the category. — PR
- D3 Bio presented AACR 2026 updates and said its KRAS G12C inhibitor elisrasib showed Phase 2 efficacy across multiple tumor types. Such readouts can influence partnering interest and crowded KRAS dynamics. — PR
- Mabwell said it will present clinical data for Nectin-4 ADC 9MW2821 in cervical cancer at ESMO GC 2026. Conference disclosures can shift perceptions of probability of success and partnering optionality. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Chiesi to acquire HAE company KalVista in $1.9B deal. — BioCentury
- Teva to acquire Emalex with $700M up front for Tourette’s asset. — BioCentury
- AstraZeneca exercised its option on Pinetree’s preclinical EGFR degrader program, triggering a $25M payment and keeping total deal value above $500M. — PR
- Formosa Pharmaceuticals, SERI partner on corneal disease formulations. — PR
VC / Private Financings
- Vivacta Bio closed a Series A and Series A+ financing of more than $50M to advance in vivo CAR-T, led by Loyal Valley Capital and Decheng Capital with OrbiMed, Hankang Capital, Eisai Innovation, C&D Emerging Industry Equity Investment, Qiming Venture Partners, Beijing Shunxi, Apricot Capital and existing backers participating. — PR
IPOs / Follow-Ons
- Avalyn Pharma priced a $300M upsized IPO at $18 per share, at the top of its marketed range, to fund inhaled pulmonary-fibrosis programs. — BioPharma Dive
- Valneva completed an €84M reserved offering. — PR
Academic Corner - Membranoproliferative Glomerulonephritis Due to Cryoglobulinemia. — NEJM
- Tuning the immune response to mRNA vaccines. — Nature Biotech
- mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression. — Nature Biotech
- Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial. — Nature Medicine
- An agentic framework for autonomous scientific discovery in cancer pathology. — Nature Medicine
- Pigmentary Changes That Developed During Pregnancy. — JAMA
- The Veteran Affairs’ Whole Health Approach for Chronic Pain Management. — JAMA
|
